The United States Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not infringe patents held by Amarin Corporation. The decision on Thursday overturns a lower court ruling and protects the "skinny label" pathway used by generic drugmakers to bypass brand-name patents. This ruling preserves a system that generic firms claim saved payers $2.9 trillion over the last decade by lowering drug costs.

Protecting the Skinny Label Pathway